

Impact Highlights

Year in review: 2021

IMPROVING PATIENT ACCESS AND AFFORDABILITY

About **70**
price negotiation meetings conducted with manufacturers to secure better prices for selected drugs and medical devices

About **30**
price negotiation sessions conducted jointly with ALPS and vendors to secure target prices for implants

SUPPORTING GREATER ADOPTION OF CLINICALLY EFFECTIVE AND COST-EFFECTIVE TREATMENTS

Completed
comprehensive drug margin analysis to support the review of public healthcare finance policy

571
implant models listed on Medical Technology Subsidy List (MTSL)

61 Health Technology Assessments (HTAs) completed on cancer drug list review

30 HTAs completed on other health technologies

47 Topics approved for subsidy

17 Health technology guidances published

11 Utilisation reports produced

8 Local cost-effectiveness analyses conducted

7 Outcomes evaluation reports produced

5 Manuscripts published

2021 Impact Highlights

DRIVING ADOPTION OF APPROPRIATE CARE

Inaugural **“Health Technology Assessment & the Art of Decision-making Workshop”** to equip healthcare professionals with practical knowledge and skills; full attendance by healthcare professionals from all three healthcare clusters

8 clinical recommendations for appropriate use of chest X-rays and interventions to manage pre-diabetes

3 CPE webinar videos released

2 clinician and patient education resources published

Publication of **ACE Insights**, a biannual e-bulletin for healthcare professionals

2437 person-hours of guided Continuing Professional Education (CPE) provided through one-to-one personalised educational visiting with ACE Clinical Update Service (CUES) and

4 mass professional education meetings

50 collaborations with clinical experts on

ACE Clinical Guidances (ACGs), with **13** formal endorsements from professional bodies

Electronic direct mailers

(eDMs) to reinforce key clinical messages for sustained practice change



EDUCATING PATIENTS ON CLINICALLY EFFECTIVE AND COST-EFFECTIVE CARE

New **Consumer Engagement and Education (CEE)** workstream established to support patient involvement in ACE’s technical work and develop educational resources for patients and carers.

Published Plain English Summaries (PES) and patient factsheets to **encourage shared decision-making** between patients and their doctors



3 HTA educational videos released



Shared about **advancing patient involvement in healthcare decision-making** at a dialogue session attended by

79 patients and carers from

25 patient organisations



ANNUAL WEBSITE METRICS



Website Pageviews

159,597



ACG Pageviews

10,392



Website Visits (sessions)

37,600



Guidance Downloads

18,427


Impact Highlights

2016-2021



More than
\$400 million
cost savings
to the healthcare system

Improved access and affordability for selected medicines and medical technologies for
more than
half a million*
patients





Member of



PPRI
Pharmaceutical Pricing and
Reimbursement Information



euroscan



INAHTA



ispe
International Society
for Pharmacoepidemiology

**Estimated annual number of patients who can benefit from the subsidised medicines and medical technologies evaluated by ACE during the first year of subsidy listing*

Cumulative Impact Highlights

ACE conducted HTA that informed funding decisions for these treatments that have been listed for subsidy. There have been significant increase in utilisation of these treatments over the years contributing to improved patient health outcomes and cost savings to the healthcare system.

ESTIMATED* IMPACT OVER FIVE YEARS

Non-vitamin K antagonist oral anticoagulants for treating atrial fibrillation

564

deaths avoided

287

hospitalisations reduced (stroke/systemic embolism)

572

hospitalisations reduced (intracranial haemorrhage/gastrointestinal bleed)

Sofosbuvir/velpatasvir for treating chronic hepatitis C

323

hepatitis C virus associated deaths avoided

250

hepatocellular carcinomas avoided

160

decompensated cirrhosis avoided

Sodium-glucose co-transporter-2 inhibitors for management of type II diabetes

391

deaths avoided

2816

all-cause hospitalisations reduced

*Benefit estimates are relative to their comparators and based on both real-world data and modelling.

Agency for Care Effectiveness

College of Medicine Building
16 College Road, Singapore
169854

Tel (65) 6325 9220
Fax (65) 6224 1677
Email ace_hta@moh.gov.sg
Web www.ace-hta.gov.sg